CSL provided an update on HAE clinical development as part of reporting on annual company results
CSL today reported financial results for the year that ended June 30, 2023, and provided a business update.
Dr. Paul McKenzie, CSL’s Chief Executive Officer and Managing Director, said, “Our strong performance in the 2023 financial year was delivered against a challenging operating environment. Our CSL Behring business rebounded strongly driven by exceptional growth in immunoglobulin sales and record plasma collections.
“We remained focused on executing on our strategy of delivering innovative medicines to best serve our patients and protect public health. This, combined with the efforts of our people is now delivering positive momentum for CSL and our patients in more than 100 countries.”
In addition to financial data, the company highlighted that its potential new once-monthly prophylactic treatment for HAE attacks, garadacimab (Anti-FXIIa), is being prepared for global regulatory submission.
(Source: CSL)
